Insight Molecular Diagnostics (IMDX) Common Equity (2020 - 2025)
Historic Common Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$9.2 million.
- Insight Molecular Diagnostics' Common Equity fell 19469.67% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 19469.67%. This contributed to the annual value of -$12.3 million for FY2024, which is 15996.68% down from last year.
- Latest data reveals that Insight Molecular Diagnostics reported Common Equity of -$9.2 million as of Q3 2025, which was down 19469.67% from $1.1 million recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Common Equity registered a high of $106.6 million during Q1 2021, and its lowest value of -$12.3 million during Q4 2024.
- Its 5-year average for Common Equity is $39.9 million, with a median of $34.3 million in 2022.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Common Equity surged by 19113.45% in 2021, and later plummeted by 19469.67% in 2025.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Common Equity stood at $65.2 million in 2021, then plummeted by 47.42% to $34.3 million in 2022, then crashed by 40.31% to $20.5 million in 2023, then plummeted by 159.97% to -$12.3 million in 2024, then increased by 25.08% to -$9.2 million in 2025.
- Its last three reported values are -$9.2 million in Q3 2025, $1.1 million for Q2 2025, and $10.2 million during Q1 2025.